NCT04774952View on ClinicalTrials.gov

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

May 6, 2024

Study Completion Date

June 28, 2024

Conditions
Solid Tumors
Interventions
DRUG

RMC-5552

RMC-5552 for IV administration

Trial Locations (8)

10021

Memorial Sloan Kettering Cancer Center, New York

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute - Tennessee Oncology, PLLC, Nashville

73104

University of Oklahoma - Stephenson Cancer Center, Oklahoma City

78712

Dell Seton Medical Center at University of Texas, Austin

92868

UC Irvine - Chao Family Comprehensive Cancer Center, Irvine

94115

UC San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco

95817

UC Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

Revolution Medicines, Inc.

INDUSTRY

NCT04774952 - Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | Biotech Hunter | Biotech Hunter